Vueway®(gadopiclenol) Authorized in the EU for Advanced MRI Imaging Bracco announces marketing authorization in European Union of Vueway® (gadopiclenol), a new macrocyclic gadolinium-based contrast agent for CE-MRI.

New Bracco and Samsung Medison Partnership Agreement Bracco Imaging partners with Samsung Medison to advance diagnostic imaging technologies and improve clinical accuracy for patient care globally.

Bracco Group Forms Bracco Japan Learn about Bracco Group’s strategic creation of Bracco Japan, expanding its imaging and diagnostic expertise into the Japanese healthcare market.

Bracco Diagnostics Inc. Branded Max 3™ received FDA 510(k) clearance Bracco Diagnostics Inc. Branded Max 3TM, a Rapid Exchange and Syringeless Injector, received FDA 510(k) clearance adding evolving innovation in Magnetic Resonance Imaging (MRI) and its product portfolio.

New Bracco Suisse and Verasonics Strategic Partnership Bracco Suisse partners with Verasonics to advance ultrasound imaging technology and enhance diagnostic capabilities for clinicians worldwide.

Bracco Diagnostics Inc. Announces Update on Product Portfolio Strategic decisions enable Bracco to serve better the needs of healthcare providers and patients with its enhanced pipeline offering.

Blue Earth Diagnostics Names Marco Campione as CEO Blue Earth Diagnostics announces Marco Campione as CEO to lead innovation in molecular imaging and diagnostic healthcare solutions worldwide.

Bracco Receives EcoVadis Gold Medal for Sustainability Again Bracco earns EcoVadis Gold for its sustainability initiatives, reaffirming its commitment to corporate responsibility and ethical practices.

Bracco at RSNA 2024: Innovation in Imaging Discover Bracco’s participation at RSNA 2024, showcasing groundbreaking diagnostic imaging solutions and educational programs for radiologists worldwide. 

CitraClear™ Introduced by Bracco Diagnostics Discover Bracco’s launch of CitraClear™, a preprocedure hydration beverage designed with patients in mind.